NOV03 met all primary and secondary sign and symptom endpoints in a second phase 3 trial investigating the therapy for dry eye disease treatment, according to a press release from Bausch + Lomb and Novaliq.
NOV03 (perfluorohexyloctane) is a drop with a novel mechanism of action designed to treat dry eye associated with meibomian gland dysfunction. MOJAVE, a prospective, multicenter, randomized, double-masked, saline-controlled phase 3 study, enrolled 620 participants who received either NOV03 or placebo four times a day.
The change from baseline in total corneal fluorescein staining became